Certain Pharmaceuticals and Intermediate Chemicals: Identification of Applicable 6-Digit HS Subheadings for Products Covered By

Total Page:16

File Type:pdf, Size:1020Kb

Certain Pharmaceuticals and Intermediate Chemicals: Identification of Applicable 6-Digit HS Subheadings for Products Covered By Second Interim Report to the Public on CERTAIN PHARMACEUTICALS AND INTERMEDIATE CHEMICALS: IDENTIFI­ CATION OF APPLICABLE 6-DIGIT HS SUBHEADINGS. .· FOR PRODUCTS ·coVERED BY THE PROPOSED URUGUAY ROUND PHARMACEUTICAL A,GREEMENT Investigation No. 332-322 USITC PUBLICATION 2500 APRIL 1992 ,f~· United States International Trade Commission . ·J, Washington, DC 20436 . ·-~}~~:; . _:, -~;<$f ·!•;. UNITED STATES INTERNATIONAL TRADE COMMISSION COMMISSIONERS Don E. Newquist, Chairman Anne E. Brunsdale, Vice Chairman David B. Rohr Carol T. Crawford Janet A. Nuzum Peter S. Watson Office of Operations Charles W. Ervin, Director Office of Industries Rohen A. Rogowsky, Director This report was prepared principally by Eli?.abcth R. Ncsbiu Project Leader Aimison Jonnard Edward Matusik David Michels James Raftery Office of Industries David Beck Office of Tariff Affairs and Trade Agreements With assistance from Paul Daniels James Gill Office ofInformation Resources Management Under the direction of John J. Gersic, Chief Energy & Chemicals Division and Edmund D. Cappuccilli, Chief Energy, Petroleum, Benzenoid Chemicals, and Rubber and Plastics Branch · Energy & Chemicals Division Additional assistance provided by Brenda Carroll and Keilh Hipp With special assistance from U.S. Customs Service Address all communications to Kenneth R. Mason, Secreta·ry to the Commission United States International Trade Commission Washington, DC 20436 PREFACE This report is the second of two interim reports to the public pertaining to Commission investigation No. 332-322, entitled Certain Pharmaceuticals and Intermediate Chemicals; Identification of Applicable 6-Digit HS Subheadings for Products Covered by the Proposed Uruguay Round Pharmaceutical Agreement. The investigation was instituted following receipt of a letter from the United States Trade Representative (USTR) on January 27, 1992, requesting that the Commission conduct an investigation under section 332(g) of the Tariff Act of 1930 (see appendix A for a copy of the USTR' s request)·. The Commission was also asked to identify each instance where there is a known difference in ~inion among countries on the classification of a product. USTR has requested the Commissioner of the U.S. Customs Service (Customs) to provide Commission staff with any necessary technical assistance. The USTR asked the Commission to submit its report by June 1, 1992. The purpose of the investigation is to provide the USTR with a rE[!port listing the 6-digit Harmonized Commodity Description and Coding System (HS) subheadings for those pharmaceuticals having an International Non-proprietary Name (INN) and certain intermediate chemical products (used primarily in the production of pharmaceuticals) to be covered under the proposed nzero-for-zeron initiative on pharmaceuticals. This initiative, currently being negotiated under the Uruguay Round market access negotiations, provides for reciprocal duty-free treatment among major trading partners for pharmaceuticals and certain intermediate chemical products. As of the date of institution of this investigation, the request from the USTR regarding this initiative covered a total of 6,085- INNs and 272 intermediate chemicals. Inasmuch as the USTR asked that the Commission make its work available to the USTR and the public on a flow basis, the Commission plans, as indicated in the Commission's notice of institution, reproduced in appendix B of this report as published in the Federal Register, to make available two interim reports to the public. Each interim report will contain a listing of the classifications completed by that phase of the investigation. These preliminary 6-digit HS classifications were derived on the basis that the chemical names provided represented separate chemically defined compounds. No public hearing will be held in connection with this investigation. However, interested parties are requested to submit written statements to the Commission regarding any discrepancies between their current classifications for the chemicals under consideration and the classifications presented by the Commission. The deadline for submissions regarding this second interim report is close of business (5;15 pm) on May 8, 1992 (see appendix B for more information) . Proof of such classification discrepancies are requested either in the form of either official rulings by the U.S. Customs Service (Customs) or copies of prior communications with Customs on this issue. The Commission will work with Customs personnel to resolve any classification discrepancies presented by interested parties. It should be noted that the classifications presented in the Commission's report(s) are not intended to be and wil_l not be binding upon the Customs Service and should not be considered formal or informal rulings or advice. i CONTENTS Preface i Tables 1. Tariff Classifications: Phannaceuticals having an INN and their corresponding HTS subheadings 1 Appendices A. Copy of the letter of request from the United States Trade Representative A-1 B. Copy of the Commission's notice of institution of investigation, as published in the Fesieral Register B-1 iii Table 1 Tariff Classifications: Pharmaceuticals having an INN and their corresponding HTS subheadings (One asterisk (*) denotes INN names for radicals and groups proposed by the World Health Organization. Two asterisks (**) indicate that either structural information was not available at time of classification or description is too general to classify.) HTS HTS subheading INN subheading INN 2924.10 ACBNBORAMIC ACID 3003.90 BUTHALITAL SODIUM * ACBTORATB 2931.60 CALCIUM SODIUM FBRRICLATB * ACISTRATB * CAMSILATB 2936.10 ACITRBTIN * CARBBSILATB 2918.21 ADAPALBNB 2931.00 CARBOPLATIN 2926.90 ALMOKALANT 2933. 71 CARMOFOR 2914. 70 AMCINAFAL 3001.20 CARPBRITIDB 2914. 70 AMCINAFIDB 2924.29 CASOKBFAMIDB ** AMINOACID 2934.10 CBFCLIDIN 2933.71 AMPHBNIDONB 2934.10 CBFDALOXIMB 2922.30 AMRUBICIN 2941.90 CBFDINIR 2933.90 AMTOLMBTIN GUACIL 2934.10 CBFBMPIDONB .... 2937.99 ANAGBSTONB 2941.90 CBFBPIMB 2933 .59 ANAGRBLIDB 2934.10 CBFBTBCOL 293'. 90 APRIKALIM 2941.90 CBFMBPIDIUM CHLORIDE 2940.00 APROSULATB SODIUM 2934.10 CBFQUINOMB 2922.49 ARAPROFBN 2934.10 CBFTBRAM * AXBTIL 2934.10 CBFUZONAM 2933.39 BARNIDIPINB 3001.90 CBLMOLBOKIN 2934.90 BBCLICONAZOLB ** CBTRORBLIX 2937.29 BBCLOMBTASONB ** CHOLINB ALFOSCBRATB 2916.31 BBMBSBTRON 2918.90 CICAPROST 2933.90 BBRTOSAMIL 2937.99 CICLBSONIDB * BBSILATB 2934.90 CICLBTANINB 2922.49 BBTAMIPRON * CICLOTATB * BBZOMIL 2931.00 CIDBFBRRON 2934.90 BIMAJCALIM 2934.90 CIFOSTODINB 2933.90 BINDARIT 2933.90 CILAZAPRILAT 2934.90 BINOSPIRONB 2933.39 CILOBRADINB 2939.90 BIORBSMBTHRIN 2933.90 CILOFUNGIN 2933 .90 BRINAZARONB 2933.29 CILUTAZOLINB 2939.90 BROVINCAMINB 2926.90 CIMATBROL 2937.21 BUDBSONIDB 2934.90 CINOXOPAZIDB * BUNAPSILATB 2914 .50 CIOTSRONBL * BUTBPRATB * CIPIONATB Table 1--Continued Tariff Classifications: Pharmaceuticals having an INN and their corresponding HTS subheadings (One asterisk (*) denotes INN names for radicals and groups proposed by the World Health Organization. Two asterisks (**) indicate that either structural information was not available at time of classification or description is too general to classify.) HTS HTS subheadinq INN _subhe_adinq INN 2933.40 CIPRBFADOL 2928.00 DBFBROXAMINB 2933.40 CIPROQUINATB 3913.90 DBFIBROTIDB 2934.90 CISCONAZOLB 2934.90 DBFLAZACORT 2930.90 CISTINBXINB 2929.90 DBFOSFAMIDB 2934.90 CITATBPINB 2939.90 DBHYDROBMBTINB 2924.21 CLANFBNUR 2914 .29 DBLANTBRONB 2941.50 CLARITHROMYCIN 2922.49 DBLAPRIL 2933 .69 CLAZURIL 2939.60 DBLBRGOTRILB 2934.90 CLBNTIAZBM 2935.00 DBLFANTRINB 2933.40 CLIMIQUALINB 2933.90 DBLFAPRAZINB 2922.29 CLIROPAMINB 2937.90 DBLMADINONB 2922.50 CLOMIFBNOXIDB 2933.90 DBLMBTACIN 2934 .,90 CLOPIDOGRBL 2934.90 DBLMOPINOL "' •• CLOSILATB 2933.90 DBLORAZBPAM •• CORTICORBLIN 2917.19 DBLOXOLONB •• CRILANOMBR 2918.90 DBLPROSTBNATB •• CROBBFATB 2903.69 DBMBRBXINB •• CROMACATB 2924.29 DBMBCARIUM BROMIDB •• CROMBSILATB 2939.90 DBMBCOLCINB •• DALFOPRISTIN 2941.30 DBMBCYCLINB •• DALTBPARIN SODIUM 2914 .29 DBMBGBSTONB •• DAJNASTATIN 2921.49 DBMBLV8RINB •• DAPOXBTINB 2928.00 DBMBXIPTILINB •• DBANIL 2933.29 DBMOCONAZOLB •• DBBROPOL 2934.90 DBMOXYTOCIN •• DBCIL 2924.29 DBNATONIUM BBNZOATB 2924.29 DBCIMBMIDB 2922.50 DBNAVBRINB 2934.90 DBCITABINB 2933.90 DBNBUFYLLINB 2933.39 DBCITROPINB 2918.90 DBNIPRIDB 2933.39 DBCLBNPBRONB 2922.50 DBNOPAMINB 2933.59 DBCLOXIZINB 2933.90 DBNPIDAZONB 2922.50 DBCOMINOL 2933.29 DBNZIMOL 2933.90 DBCOQUINATB 2933.90 DBPRAMINB 2921.19 DBCTAFLUR 2937.29 DBPRODONB 2923.90 DBDITONIUM BROMIDE 2918.90 DBPRQSTIL Table 1--Continued Tariff Classifications: Pharmaceuticals having an INN and their corresponding HTS subheadings (One asterisk (*) denotes INN names for radicals and groups proposed by the World Health Organization. Two asterisks (**) indicate that either structural information was not available at time of classification or description is too general to classify.) HTS HTS subheadine:t .. _ _lmi___ __ subheadine:t INN 2933.39 DBPTROPINB 2933.90 DBXCLAMOL 2933.40 DBQUALINIUM CHLORIDB 2933.39 DBXBTIMIDB ** DBRAMCICLANB 2934.10 DBXBTOZOLINB 2939.90 DBRPANICATB 2921.59 DBXFBNFLURAMINB 2914 .69 DBSASPIDIN 2916.39 DBXIBUPROFBN 2933.90 DBSCICLOVIR 2933.90 DBXIMAFBN 2932.90 DBSCINOLONB 2933.79 DBXINDOPROFBN 2939.90 DBSBRPIDINB 2933.39 DBXIVACAINB 2909.19 DBSFLURANB 2933.29 DBXLOFBXIDINB 2933.90 DBSGLUGASTRIN ** DBXLOXIGLUMIDB 2933.90 DBSIPRAMINB 2933.90 DBXMBDBTOMIDINB 2938.90 DBSLANOSIDB· ** I DBXNAFBNODONB w 2937.99 DBSLORBLIN 2930.90 DBXORMAPLATIN 2924.29 DBSMBTHYLMORAMIDB
Recommended publications
  • Scanned Using Fujitsu 6670 Scanner and Scandall Pro Ver 1.7 Software
    554 1993/115 THE DRUG TARIFF 1998 PURSUANT to section 99 of the Social Security Act 1964, the Minister of Health hereby gives the following direction. ANALYSIS PART V ABATEMENTS 15. Group 2 cardholders 1. Title and commencement 16. Certain other cardholders 2. Interpretation 17. Contraceptives 18. Requirements in excess of 20 PART I 19. Class B controlled drugs REQ.UIREMENTS 20. The Hokianga 3. Requirements generally 4. Certain requirements excluded 5. Standards PART VI PRIGING PART II 21. Application of Pricing Schedules PERIOD AND QUANTITY OF SUPPLY 22. Computation of selling price 6. Doctors' and midwives' prescriptions 23. Rounding calculations (other than oral contraceptives) 24. Minimum charges 7. Oral contraceptives 25. Water 8. Dentists' prescriptions 26. Payments for bulk supply orders 9. Original packs, and certain antibiotics 27. Payment for practitioners' supply orders PART III 28. Allergy treatment sets CHARGES 29. Disputes 10. Restriction on charges I!. Part charges 12. Other permitted charges PART VII MISCELLANEOUS PROVISIONS PART IV 30. Claims on Department CALCULATION OF PAYMENTS 31. Bulk supply orders 13. Requirements other than hypodermic 32. Practitioner's supply orders syringes and needles 33. Wholesale supply orders 14. Hypodermic syringes and non· 34. Revocations and savings disposable hypodermic needles Schedules 1993/115 Drug Tariff 1993 555 DIRECTION 1. Tide and commencement-(I) This direction may be cited as the Drug Tariff 1993. (2) This direction shall come into force on the 1st day of May 1993. 2. Interpretation-(I)
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0197411A1 Gao Et Al
    US 2004O197411A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0197411A1 Gao et al. (43) Pub. Date: Oct. 7, 2004 (54) ACCEPTABLY NON-HYGROSCOPIC Related U.S. Application Data FORMULATION INTERMEDIATE COMPRISINGA HYGROSCOPIC DRUG (60) Provisional application No. 60/435,147, filed on Dec. 19, 2002. Provisional application No. 60/435,022, (76) Inventors: Danchen Gao, Chicago, IL (US); Ann filed on Dec. 19, 2002. Provisional application No. M. Czyzewski, Grayslake, IL (US) 60/435,422, filed on Dec. 19, 2002. Correspondence Address: Publication Classification PHARMACIA CORPORATION 7 GLOBAL PATENT DEPARTMENT 8. s - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Ales POST OFFICE BOX 1027 Oa - 1 - O - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - ST. LOUIS, MO 63006 (US) (57) ABSTRACT A Solid particulate composition is provided comprising a (21) Appl. No.: 10/741,530 hygroscopic and/or deliqueScent drug and at least one non hygroscopic polymer. The drug and the at least one polymer are in intimate association and the composition is acceptably (22) Filed: Dec. 18, 2003 non-hygroscopic. Patent Application Publication Oct. 7, 2004 Sheet 1 of 3 US 2004/0197411A1 FIG. 1 40 Mass Increase (%) 20 -- Compound 1 10 RH (%) Mass Increase (%) O 2O 40 60 80 1 OO 120 140 Time (h) Patent Application Publication Oct. 7, 2004 Sheet 2 of 3 US 2004/0197411A1 MaSS increase (%) O 2O 40 60 80 1 OO 12O 140 Mass Increase (%) O 1 OO 2OO 3OO 400 5 OO Patent Application Publication Oct. 7, 2004 Sheet 3 of 3 US 2004/0197411A1 F.G. 5 Mass Increase (%) O 2O 40 6O 8O 1 OO 12O 140 160 US 2004/O1974 11 A1 Oct.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Topical and Systemic Antifungal Therapy for Chronic Rhinosinusitis (Protocol)
    CORE Metadata, citation and similar papers at core.ac.uk Provided by University of East Anglia digital repository Cochrane Database of Systematic Reviews Topical and systemic antifungal therapy for chronic rhinosinusitis (Protocol) Head K, Sacks PL, Chong LY, Hopkins C, Philpott C Head K, Sacks PL, Chong LY, Hopkins C, Philpott C. Topical and systemic antifungal therapy for chronic rhinosinusitis. Cochrane Database of Systematic Reviews 2016, Issue 11. Art. No.: CD012453. DOI: 10.1002/14651858.CD012453. www.cochranelibrary.com Topical and systemic antifungal therapy for chronic rhinosinusitis (Protocol) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 BACKGROUND .................................... 1 OBJECTIVES ..................................... 3 METHODS ...................................... 3 ACKNOWLEDGEMENTS . 8 REFERENCES ..................................... 9 APPENDICES ..................................... 10 CONTRIBUTIONSOFAUTHORS . 25 DECLARATIONSOFINTEREST . 26 SOURCESOFSUPPORT . 26 NOTES........................................ 26 Topical and systemic antifungal therapy for chronic rhinosinusitis (Protocol) i Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Protocol] Topical and systemic antifungal therapy for chronic rhinosinusitis Karen Head1, Peta-Lee Sacks2, Lee Yee Chong1, Claire Hopkins3, Carl Philpott4 1UK Cochrane Centre,
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • Sustained-Release Compositions Containing Cation Exchange Resins and Polycarboxylic Polymers
    ~" ' Nil II II II II Ml Ml INI MINI II J European Patent Office *»%r\ n » © Publication number: 0 429 732 B1 Office_„. europeen des brevets © EUROPEAN PATENT SPECIFICATION © Date of publication of patent specification: 16.03.94 © Int. CI.5: A61 K 9/06, A61 K 9/1 8, A61 K 47/32 © Application number: 89312590.6 @ Date of filing: 01.12.89 © Sustained-release compositions containing cation exchange resins and polycarboxylic polymers. @ Date of publication of application: (73) Proprietor: ALCON LABORATORIES, INC. 05.06.91 Bulletin 91/23 6201 South Freeway Fort Worth Texas 76107(US) © Publication of the grant of the patent: 16.03.94 Bulletin 94/11 @ Inventor: Janl, Rajni 4621 Briarhaven Road © Designated Contracting States: Fort Worth, Texas 76109(US) AT BE CH DE FR GB IT LI LU NL SE Inventor: Harris, Robert Gregg 3224 Westcliff Road W. © References cited: Fort Worth, Texas 76109(US) EP-A- 0 254 822 J.Pharm. SCI., vol. 60, no. 9, September 1971, © Representative: Jump, Timothy John Simon et pages 1343-1345 A. HEYD:"Polymer-drug in- al teraction: stability of aqueous gels contain- Venner Shipley & Co. ing neomycin sulfate" 20 Little Britain London EC1A 7DH (GB) 00 CM CO o> CM Note: Within nine months from the publication of the mention of the grant of the European patent, any person ® may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition CL shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee LU has been paid (Art.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Discovery of New Antimicrobial Agents Using Combinatorial Chemistry
    Wright State University CORE Scholar Browse all Theses and Dissertations Theses and Dissertations 2007 Discovery of New Antimicrobial Agents using Combinatorial Chemistry William I. Northern Wright State University Follow this and additional works at: https://corescholar.libraries.wright.edu/etd_all Part of the Immunology and Infectious Disease Commons, and the Microbiology Commons Repository Citation Northern, William I., "Discovery of New Antimicrobial Agents using Combinatorial Chemistry" (2007). Browse all Theses and Dissertations. 206. https://corescholar.libraries.wright.edu/etd_all/206 This Thesis is brought to you for free and open access by the Theses and Dissertations at CORE Scholar. It has been accepted for inclusion in Browse all Theses and Dissertations by an authorized administrator of CORE Scholar. For more information, please contact [email protected]. DISCOVERY OF NEW ANTIMICROBIAL AGENTS USING COMBINATORIAL CHEMISTRY A thesis submitted in partial fulfillment Of the requirements for the degree of Master of Science By WILLIAM ISAAC NORTHERN B.S., University of Cincinnati, 1982 2007 Wright State University WRIGHT STATE UNIVERSITY SCHOOL OF GRADUATE STUDIES October 29, 2007 I HEREBY RECOMMEND THAT THE THESIS PREPAIRED UNDER MY SUPERVISION BY William Isaac Northern ENTITLED Discovery of New Antimicrobial Agents Using Combinatorial Chemistry BE ACCEPTED IN PARTIAL FULFULLMENT OF THE REQUIREMENTS FOR THE DEGREE OF Master of Science ______________________________ Nancy Bigley, Ph.D. Thesis Director ______________________________ Barbara Hull, Ph.D. Department Chair Committee on Final Examination ______________________________ Nancy Bigley. Ph.D. ______________________________ Barbara Hull, Ph.D. ______________________________ Daniel Ketcha, Ph.D. ______________________________ Gerald Alter, Ph.D. ______________________________ Joseph F. Thomas, Jr., Ph.D. Dean, School of Graduate Studies ABSTRACT Northern, William Isaac.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2007/0155676 A1 Burnett Et Al
    US 20070 155676A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0155676 A1 Burnett et al. (43) Pub. Date: Jul. 5, 2007 (54) SUBSTITUTED AZETIONONE (60) Provisional application No. 60/452,725, filed on Mar. COMPOUNDS, PROCESSES FOR 7, 2003. PREPARING THE SAME, FORMULATIONS AND USES THEREOF Publication Classification (75) Inventors: Duane A. Burnett, Bernardsville, NJ (51) Int. Cl. (US); John W. Clader, Cranford, NJ A61K 3 1/7052 (2006.01) (US) A6II 3 L/506 (2006.01) A61K 31/4709 (2006.01) Correspondence Address: A61K 31/4025 (2006.01) SCHERING-PLOUGH CORPORATION A61K 31/4439 (2006.01) PATENT DEPARTMENT (K-6-1, 1990) A 6LX 3L/397 (2006.01) 2000 GALLOPNG HILL ROAD C07D 405/14 (2006.01) KENILWORTH, NJ 07033-0530 (US) C07D 405/02 (2006.01) (52) U.S. Cl. ..................... 514/23: 514/210.02:536/17.3; (73) Assignee: Schering Corporation, Kenilworth, NJ 54O72OO (21) Appl. No.: 11/708,449 (57) ABSTRACT Filed: Feb. 20, 2007 The present invention provides substituted azetidinone com (22) pounds, formulations and processes for preparing the same Related U.S. Application Data which can be useful for treating vascular conditions such as atherosclerosis or hypercholesterolemia, diabetes, obesity, (62) Division of application No. 10/792.346, filed on Mar. stroke, demyelination and lowering plasma levels of sterols 3, 2004, now Pat. No. 7,208,486. and/or stanols in a subject. US 2007/O 155676 A1 Jul. 5, 2007 SUBSTITUTED AZETIDINONE COMPOUNDS, 0006 U.S. Pat. Nos. 5,846,966 and 5,661,145, respec PROCESSES FOR PREPARING THE SAME, tively, disclose treatments for inhibiting atherosclerosis and FORMULATIONS AND USES THEREOF reducing plasma cholesterol levels using Such hydroxy Substituted aZetidinone compounds or Substituted B-lactam CROSS-REFERENCE TO RELATED compounds in combination with HMG CoA reductase APPLICATION inhibitor compounds, which act by blocking hydroxymeth 0001.
    [Show full text]